Key Insights

Highlights

Success Rate

67% trial completion

Published Results

15 trials with published results (16%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

13.5%

13 terminated out of 96 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

1%

1 trials in Phase 3/4

Results Transparency

58%

15 of 26 completed with results

Key Signals

15 with results67% success13 terminated

Data Visualizations

Phase Distribution

82Total
Not Applicable (15)
Early P 1 (12)
P 1 (33)
P 2 (21)
P 4 (1)

Trial Status

Recruiting35
Completed26
Terminated13
Unknown6
Active Not Recruiting5
Not Yet Recruiting5

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 26 completed trials

Clinical Trials (96)

Showing 20 of 20 trials
NCT05565118Phase 1RecruitingPrimary

Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

NCT07416188Phase 1Not Yet Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

NCT05538130Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05835687Phase 1Recruiting

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

NCT07210632Early Phase 1Recruiting

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT04099797Phase 1Recruiting

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

NCT04573140Phase 1Recruiting

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

NCT03334305Phase 1Terminated

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

NCT06528691Phase 2RecruitingPrimary

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

NCT05843253Phase 2RecruitingPrimary

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

NCT03340506Phase 4Recruiting

Dabrafenib and/or Trametinib Rollover Study

NCT03952598Phase 2Suspended

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

NCT04485559Phase 1Suspended

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

NCT05278208Phase 1RecruitingPrimary

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

NCT05096481Phase 2RecruitingPrimary

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT07206849Phase 2Not Yet Recruiting

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

NCT05839379RecruitingPrimary

Targeted Pediatric High-Grade Glioma Therapy

NCT07499141CompletedPrimary

Use of Fluorescence in Gliomas

NCT03605550Phase 1Active Not RecruitingPrimary

A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

NCT05212272Not ApplicableRecruitingPrimary

MRI in High-Grade Glioma Patients Undergoing Chemoradiation

Scroll to load more

Research Network

Activity Timeline